From Elad Katz’s experience

Making phenotypic drug screens reproducible at 384-well scale

At the University of Dundee's Drug Discovery Unit, Elad managed small-molecule screening cascades and engineered reproducible 384-well phenotypic assays for ciliopathies and complex signaling targets.

Industry
Health and life sciences
Organization
Drug Discovery Unit, University of Dundee
Elad’s role
Managed small-molecule screening cascades

The business need

The Drug Discovery Unit (DDU) at the University of Dundee runs small-molecule drug discovery programs. Its work on ciliopathies and complex signaling targets needed phenotypic assays, which read a compound's effect from how cells behave, that hold up reproducibly in 384-well high-throughput screening.

What Elad did

  1. Managed small-molecule screening cascades at the DDU.
  2. Engineered reproducible 384-well high-throughput phenotypic assays for ciliopathies.
  3. Engineered assays in the same format for complex signaling targets.
  4. Co-authored the DDU's published work on topical soft-drug modulators of the S1PR1 receptor (2018 and 2019), a program that started from the oral drug ponesimod, which showed efficacy in a psoriasis trial but caused systemic effects.

Technology and approach

  • Reproducible 384-well high-throughput phenotypic assays

Decisions this experience speaks to

  • We're building a drug discovery or disease-modelling platform and aren't sure it's compatible with how pharma and biotech customers actually run their screening workflows - how do we find out?
  • We have promising preclinical data, but we don't know if it's strong enough, or the right kind of evidence, to support a partnership or licensing conversation?

Related services and use cases

Sources

  1. Elad Katz’s profile on CTO Grand Rounds
  2. Discovery of super soft-drug modulators of S1PR1 - University of Dundee Discovery Portal (opens in a new tab)
  3. Elad Katz, Honorary Research Fellow - University of Dundee Discovery Portal (opens in a new tab)